Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

enthalten in: Hematological Oncology | 2022

von Bruzzese, A. | Derudas, D. | Galli, M. | +57

Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients : italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials

enthalten in: Hematological Oncology | 2022

von Martino, E. | Conticello, C. | Zamagni, E. | +30